Almotriptan (Axert) vs Meloxicam/Rizatriptan (Symbravo)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Migraine
Shared mechanism: 5-HT1B/1D receptor · full Migraine pipeline
Almotriptan (Axert)
Rights held by Almirall and partners
NCT00257010 · Phase 3 · completed
This was a single-group, open-label study with 447 enrolled participants and no placebo or active comparator, so the reported pain-free headache counts cannot establish how much benefit was caused by almotriptan. The primary endpoint was a clinical migraine outcome, but no between-group comparison or statistical test was possible.
No aligned efficacy figure on record for this race.
Meloxicam/Rizatriptan (Symbravo)
Marketed by Axsome Therapeutics
NCT03896009 · Phase 3 · completed
The trial was a large, randomized, double-blind, placebo- and active-controlled study with 1,594 participants. Both prespecified primary clinical endpoints were statistically significant in favor of the meloxicam/rizatriptan combination versus placebo: 2-hour headache pain freedom and absence of the most bothersome symptom.
Reported efficacy
Long-term Safety of Chronic Intermittent Use of AXS-07 (Up to 12 months): Long-term Safety of Chronic Intermittent Use of AXS-07 (Up to 12 months): AXS-07 — Subjects with any TEAEs: 293 Participants; Subjects with suspected to be drug-related TEAEs: 118 Participants; Subjects with serious TEAEs: 8 Participants; Subjects with TEAEs that led to drug withdrawal: 10 Participants; Subjects with TEAEs that led to withdrawal from study: 13 Participants; Subjects with TEAEs that resulted in death: 0 Participants (not_applicable)
Result source: NCT04068051
Results for Migraine
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Almotriptan (Axert): registry results are on file for Migraine, but their comparison mappings are not yet available.
Meloxicam/Rizatriptan (Symbravo): registry results are on file for Migraine, but their comparison mappings are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Almotriptan (Axert)'s landscape · Meloxicam/Rizatriptan (Symbravo)'s landscape